1	Original	article

3	Short-term creatine supplementation may alleviate the malnutrition-inflammation score
4	and lean body mass loss in hemodialysis patients: a pilot randomized placebo-controlled
5	trial
6	
7	Running title: Creatine supplementation and lean body mass
8	
9	Ana Clara B Marini ¹ , Reika D Motobu ¹ , Ana T V Freitas ¹ , João F Mota ¹ , Benjamin T Wall ² ,
10	Claude Pichard ³ , Alessandro Laviano ⁴ , Gustavo D Pimentel ¹ *
11	
12	1. Faculty of Nutrition, LABINCE, Federal University of Goias, GO, Brazil.
13	2. Department of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom.
14	3. Clinical Nutrition, Geneva University Hospital, Geneva, Switzerland.
15	4. Department of Clinical Medicine, Sapienza University, Rome, Italy.
16	
17	
18	
19	*Corresponding author:
20	Gustavo Duarte Pimentel
21	Faculdade de Nutrição, Universidade Federal de Goiás
22	Rua 227, Quadra 68 s/n°, Setor Leste Universitário
23	Goiânia, GO, Brasil, CEP: 74605080
24	Email: gupimentel@yahoo.com.br
25	

26 Clinical Relevancy Statement

Patients undergoing hemodialysis induces an imbalance between muscle protein synthesis and breakdown, leading to loss of muscle mass and function. This study found that short-term creatine supplementation attenuates the malnutrition-inflammation score and the lean body mass when compared to placebo.

Background: Creatine supplementation has been proposed to alleviate muscle loss in various populations, but has not been investigated in hemodialysis (HD) patients. Thus, our objective was to evaluate whether creatine supplementation could attenuate the loss of lean body mass (LBM) and malnutrition-inflammation score (MIS) in HD patients. **Methods**: A randomized, placebo-controlled, double blind, parallel-design study included HD patients, of both sexes, aged 18-59 years. The patients were allocated to a Placebo Group (PG n=15; received maltodextrin, 1st week: 40g/day and 2nd-4th weeks: 10g/day) and a Creatine Group (CG n=15; received creatine plus maltodextrin, 1st week: 20g/day of creatine plus 20g/day of maltodextrin and 2nd-4th weeks: 5g/day of creatine plus 5g/day of maltodextrin).Pre and post the intervention, patients were evaluated for food intake, MIS, body composition and biochemical parameters. **Results**: CG group attenuated the MIS (Pre:5.57±0.72 *vs*.

Post:3.85±0.47 score, p=0.003) compared with PG (Pre:5.71±0.97 vs. Post:5.36±0.95 score, p=0.317) (supplement x time p=0.017, effect size:0.964). The change of LBM was greater in CG than in PG (CG: \triangle 0.95 vs PG: \triangle 0.13 kg). At post-intervention, 28.6% of PG patients presented LBM loss and 71.4% remain stable. In contrast, 14.4 % of CG patients had LBM loss, 42.8% remain stable and 42.8% gained. Food intake and quality of life did not change. CG increased the BMI and gait speed in post- compared to pre-moment, but no difference among the groups. **Conclusion**: In HD patients, four weeks of creatine supplementation may alleviate the MIS as well as attenuate the LBM loss compared to placebo.

Keywords: creatine, hemodialysis, lean body mass, inflammation.

76 Background

The malnutrition-inflammatory score (MIS) is commonly associated with morbidity 77 and mortality in chronic kidney disease (CKD) patients undergoing hemodialysis (HD)[1] 78 79 and non-dialyzed patients [2]. Additionally, a Brazilian study revealed that the MIS is a useful tool to evaluate the protein-energy wasting (PEW) in CKD patients [2]. Considering 80 that PEW is a condition of reduced body protein and energy stores [3]and that reduced lean 81 body mass (LBM) is negatively associated with MIS [4], a new therapeutic strategy to 82 attenuate LBM loss and MIS values may improve the clinical outcome and the quality of life 83 84 (QoL) of HD patients.

Creatine supplementation has been proposed to alleviate muscle loss in various populations [5]. Kley et al. [6]in a meta-analysis found that creatine supplementation in patients with muscular my opathies was well tolerated and may lead to an increase in muscle strength and LBM. However, the impact of creatine supplementation on LBM, MIS and QoL has not been investigated in HD patients.

90 Creatine supplementation may enhance muscular phosphor creatine stores and stimulate rapid recovery of adenosine triphosphate levels [7, 8]. In addition, water retention 91 due to Cr-induced reduction in ionic strength may contribute to the gain of body weight, 92 LBM and muscle strength [9]. Considering that creatine supplementation is safe, inexpensive 93 94 and appears to positively modulate body composition in wasting and dialysis patients [8, 10, 95 11], we hypothesized that four weeks of creatine monohydrate supplementation would lower the MIS and the LBM loss in HD patients. Thus, our objective was to evaluate whether 96 creatine supplementation could attenuate the loss of LBM and MIS in CKD patients 97 98 undergoing HD.

100 Materials and Methods

101 *Design of study*

102 This randomized, placebo controlled and double blind clinical trial was conducted 103 with patients of both sexes diagnosed with CKD undergoing HD, aged between 18 and 59 104 years. The overall study lasted six weeks, and the intervention with creatine was four weeks.

After inclusion of the patients in the study, they were randomly allocated by gender, age and LBM content. The patients signed the Informed Consent Form approved by the Research Ethics Committee of the Federal University of Goiás, number 1.470.351 and this study is part of a larger trial looking at various interventions that was previous registered in the Brazilian Registry of Clinical Trials under the code RBR-98wzgn.

110

111 Recruitment and sample selection

112 The sample and criteria of inclusion was composed of patients diagnosed with CKD 113 undergoing HD treatment for more than three months at the two hemodialysis out patients' 114 clinics in Goiânia, GO, Brazil. The Gpower® 3.1 software was used to calculate the sample 115 size [12], in which a significance level of 5% with statistical power of 80%, effect size 0.50, 116 two groups and two measurements (LBM and MIS) was considered, so the study population 117 should be12 patients per group.

Exclusion criteria included patients presenting with neurological disease, severe cardiovascular diseases, physical disability (amputations, deep vein thrombosis), and patients who underwent structured physical training three months prior to the date of inclusion in the study or those already taking supplements such as creatine).

122

123

The study was performed with 30 patients divided into two groups randomized by gender, age and LBM content (**Supplementary Figure 1**): 1) Placebo Group (PG): Composed of 15 patients which received maltodextrin, and 2) Creatine Group (CG): Composed of 15 patients which received creatine monohydrate. During the intervention period, one patient in each group was excluded because of non-adherence to the creatine supplementation (90% of the recommended dose was accepted as the limit of adhesion).

The intervention was separated into 3 steps after the randomization and division of the groups (**Figure 1**): 1)during the 1st week of the study, the initial evaluations were performed including food intake assessment; MIS (see below for details); blood tests; anthropometric and body composition (dual energy X-ray absorptiometry); 2) from the 2nd to the 5th week, the intervention with the creatine and the placebo (see below); and 3) during the 6th week of the study, the same parameters were reassessed within 48 hours after the last intake of the creatine and the placebo.

139

140 *Protocol supplementation*

The blinded intervention was performed as described in Table 1. The sachets 141 containing either creatine or placebo were standardized in order to avoid any identification of 142 the content by the patients. Creatine loading phase induces an increase rapid intramuscular 143 144 creatine phosphate, which allows a small intervention period (MCKENNA et al., 2017)[U1]. [M2]Because creatine powder had no taste, whereas maltodextrin had lemon flavor, all doses 145 of creatine contained maltodextrin. Fortunately, the addition of maltodextrin to creatine 146 147 favours absorption by the gastrointestinal tract and the uptake by muscle tissue[13]. Both creatine and maltodextrin were donated by Maxtitanium®, Supley Laboratório de Alimentos 148 e Suplementos Nutricionais, Matão, SP, Brazil. 149

151

152 *Evaluation of food intake*

Food intake assessments (24h food recall) were conducted by trained nutritionists at the beginning of the intervention (1st week), during the intervention (3rd week), and at the end of the intervention (last week).The data were calculated in the Dietpro® software (5.8 version, Agromídia Softwares, Viçosa, MG, Brazil), and the macro and micronutrients consumption of the patients were quantified.

158

159 *Malnutrition-inflammation score (MIS)*

MIS is an tool based on Subjective Global Assessment (SGA), which includes three 160 161 other items, body mass index (BMI), serum albumin concentrations and total iron binding capacity (TIBC) [1, 14, 15]. MIS presents clinical history, physical and biochemical analysis 162 of the patient. The clinical history consists of addressing aspects such as weight reduction in 163 the last six months, changes in dietary intake, presence of gastrointestinal symptoms and 164 functional capacity related to nutritional status. Physical examination includes aspects such as 165 subcutaneous fat loss, muscle loss, the presence of edema resulting from malnutrition and 166 ascites which have been defined as normal, mild, moderate or severe. And biochemical 167 parameters, the albumin and TIBC exams. After completed the clinical, physical and 168 169 biochemical examinations, the results can range from 1 to 30 and then the classification of the nutritional status was performed. The score ≤ 6 presents normality and score> 6 presents 170 classification for malnutrition and high MIS [1, 14, 15]. 171

Anthropometric data were collected in the intermediate session of the week of HD (2nd session). Weight and height were evaluated by an anthropometric digital scale (Filizola®) for later calculation of BMI. In addition, arm, calf and thigh circumferences were measured using a flexible tape measure. The data were collected in duplicate by Nutritionists trained.

The body composition was assessed by dual energy X-ray absorptiometry (DXA) (Lunar DPX NT, GE Medical Systems Lunar®, Madison, USA). In this equipment collected the total fat mass and LBM. This method was chosen because muscle mass is correlated with body size, so to quantify muscle mass, the absolute level of Skeletal Muscle Mass can be adjusted for body size in different ways. Other method, such as bioimpedance only estimates the body composition from studies that performed in DXA (CRUZ-JENTOFT et al., 2019)[M3][U4]

186 *Quality of life*

QoL was assessed by Short Form 36 (SF-36) which is a well-documented healthrelated instrument consisting of 36 questions and divided into eight dimensions: physical functioning, physical role functioning, pain, general health, vitality, social role functioning, emotional role functioning, mental health. The data of this from vary from 0 to 100 (worse to best status) and have been validated in a Brazilian population [16].

192

193 Biochemical analysis

The monthly biochemical analysis performed by the clinics (pre and post serum urea, phosphorus, albumin and TIBC) were collected in the patients' medical records before and after the intervention. For the exams not performed periodically, the serum was collected by nursing and stored at -80C for subsequent quantification of serum creatinine by the chemiluminescence method in the Roche® Architect 8000 equipment.

200 Statistical analysis

The data was deposited in Microsoft Excel® and transcribed into the programs 201 202 Statistical Package of Social Sciences (SPSS) 18.0versionand e R Studio 3.4.3 version. Descriptive statistics (absolute and relative frequencies and standard error of the mean, SEM) 203 were used. The continuous variables were tested for normality by the Shapiro-Wilk Test. Chi-204 205 square test was used to evaluate categorical variables. Differences in food intake and delta of variables among the PG and CG were tested by Wilcoxon test or Mann-Whitney and Student 206 207 t test, respectively. To evaluate the interaction between supplements and intervention time, two-way ANOVA test followed post hoc of the Tukey was used. The level of statistical 208 significance was set at 5% (p < 0.05). 209

210

211 **Results**

212 Baseline characteristics and food intake

The baseline characteristics of the patients are shown in **Table 1**.Both groups were similar for sex, age, BMI and previous comorbidities (**Table 2**), and food intake (**Table 3**).

215

216 *Malnutrition-inflammation score (MIS)*

217 The MIS showed a significant reduction in CG (Δ : -1.71) compared to PG (Δ : -0.36) 218 (p= 0.01, with high effect size) (**Table 4**).

219

220 Anthropometry and body composition

Although no difference among the groups was observed (p= 0.43), both enhanced the body weight (PG Δ : 0.51 kg vs. CG Δ : 0.77 kg) and the BMI in post compared to pre moment. In addition, no change in arm, thigh and calf circumferences was found between the groups (p>0.05) (**Table 4**). In contrast, the gait speed was higher in the CG (Δ : 0.05 m/sec) than PG (Δ : -0.03 m/sec), with high effect size, but no difference among the groups.

LBM was higher in CG (Δ : 0.95 kg) than in (Δ : 0.13 kg) (ANOVA supplement x 226 227 time p= 0.03 and high effect size) and higher fat body mass in PG (Δ : 0.39 kg) than in CG (Δ : -0.17) (ANOVA supplement x time p=0.02 and high effect size) (Table 4). Additionally, 228 28.6% and 71.4% of patients of PG presented in end of intervention a LBM loss and remain 229 stable, respectively (Figure 2A). In contrast, in the CG 14.4% of patients LBM loss, 42.8% 230 remain stable and 42.8% gained (Figure 2B). Moreover, CG presented in the end of study a 231 232 reduction of delta mean fat body mass (p = 0.011, Figure 3A) and increase of delta mean LBM (p = 0.011, **Figure 3B**). 233

234

235 Biochemical analysis

Although the serum creatinine concentrations were increased in CG (Δ : 1.90 mg/dL) compared to PG (Δ : -0.82 mg/dL) (ANOVA supplement x time p= 0.001 and high effect size), serum urea pre- and post-hemodialysis concentrations and phosphorus did not alter with the treatment (p> 0.05) (**Table 4**).

240

241 *Quality of life*

242 QoL did not change in any of the eight domains assessed (Supplementary Table 1).243

244 Discussion

The present study is the first to investigate the effects of 4 weeks of creatine supplementation in patients undergoing HD. We showed that supplementation was able to alleviate the MIS and LBM loss. In addition, 43% of the CG patients gained LBM where no gain was seen in patients administered the placebo. These results corroborate with the meta-

Regarding MIS, there was a significant reduction in CG after the intervention. Of 251 note, three patients previously classified as malnourished improved to normal values. MIS is 252 an important predictor of mortality among CKD patients on HD [15]. Likewise, a Brazilian 253 observational retrospective cohort study conducted with 171 patients revealed that the 254 instrument has 53% sensitivity and 82% specificity for mortality in patients with more than 255 24 months on HD treatment. Thus, we can observe the importance of reducing the number of 256 257 previously malnourished patients, and we can infer that the reduction in the score in the group supplemented with creatine likely decreases the chances of death [18]. 258

In the CG, there was a significant increase in body weight, BMI, gait speed and 259 260 LBM. These findings corroborate with Johnston et al. 2008 study, who observed that when immobilizing the arm of healthy young and supplementing them with creatine, there was a 261 preservation of lean arm mass (+0.9%) observed by DXA whereas in the placebo group there 262 was a reduction (-3.7%) [19]. Likewise, previous studies showed that creatine 263 supplementation leads to enhanced LBM as well as body weight in young and older adults 264 [20, 21]. Similar to our study, Gotshalk et al 2008 [22] showed in older adults and elderly 265 patients that 7 days of creatine supplementation was able to increase body mass and LBM, 266 (likely, in part due to water retention) as well as to improve the time in gait test. Thus, these 267 268 data reinforce the initial hypothesis that short-term creatine supplementation can raise the LBM and improve muscle function in older people [21] and also in adults with chronic 269 disease, as observed in the present study. 270

Regarding biochemical analyses, there was a significant increase in serum creatinine concentrations in CG when compared to PG. The elevated serum creatinine levels are related to the fact that approximately 2% of daily creatine is converted into the cyclic degradation product and can leave the cells through the permeable cell membrane and enter the bloodstream without provoking toxic effects on the body[11]. Additionally, low serum creatinine concentrations (<10[6-10] md/dL), which is a good marker of nutritional status in HD patients is associated with increased mortality and reduced muscle mass [23, 24], thus we should study how poor dietary consumption impairs the loss of LBM.

According to Wallimann et al. 2017 [11], intradialytic creatine supplementation is safe and may improve the QoL of HD patients; however, in the present study, we did not observe alteration in any domains of SF-36 questionnaire. We believe the present study may encourage further research with creatine supplementation in CKD patients on HD, as we observed that creatine generated clinically relevant results, with good compliance by the patients, with no complaints of ingestion difficulties or side effects.

The present study presented positive points: 1) the use of DXA to evaluate the body composition, once it allows greater veracity in the results; 2) food intake and protein intake assessment, since we can affirm that attenuation of LBM and MIS loss were independent of food consumption, once no changes from the beginning to the end of the study were found. The main limitation of the study is: 1) we did not evaluate the hydration status which may have altered the mount of measured LBM that could be accounted for by the accumulation of intra-muscular water; 2) no physical activity test was applied.

292

293 Conclusion

In HD patients, four weeks of creatine supplementation may alleviate the MIS as well as attenuate the LBM loss compared to placebo. However, more studies are needed in the area with creatine supplementation related to muscle mass and quality of life.[M5]

297

298 Funding

299 ACBM was supported by Capes, Brazil.

300

301 Conflict of interest statements

302 All authors declare no conflict of interest

303

304 Author contributions

ACBM and GDP wrote the manuscript. ACBM and RDM participated in collection of data.

306 ACBM, ATV, JFM, BTW, CP, AL and GDP participated of analysis and interpretations of

307 data. ACBM and GDP participated of conception and design of the. All authors read and

308 approved the final manuscript. All authors contributed to the revision and approved the final

309 version of manuscript.

310

311 **References**

312

[1] Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is
 correlated with morbidity and mortality in maintenance hemodialysis patients. American journal of
 kidney diseases : the official journal of the National Kidney Foundation. 2001;38:1251-63.

316 [2] Amparo FC, Kamimura MA, Molnar MZ, Cuppari L, Lindholm B, Amodeo C, et al. Diagnostic 317 validation and prognostic significance of the Malnutrition-Inflammation Score in nondialyzed chronic

- kidney disease patients. Nephrology, dialysis, transplantation : official publication of the European
 Dialysis and Transplant Association European Renal Association. 2015;30:821-8.
- 320 [3] Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed
- nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.
 Kidney international. 2008;73:391-8.

[4] Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, et al. Association of Malnutrition Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective
 cohort study. American journal of kidney diseases : the official journal of the National Kidney

- 326 Foundation. 2009;53:298-309.
- 327 [5] Moon A, Heywood L, Rutherford S, Cobbold C. Creatine supplementation: can it improve quality
 328 of life in the elderly without associated resistance training? Current aging science. 2013;6:251-7.

[6] Kley RA, Tarnopolsky MA, Vorgerd M. Creatine treatment in muscle disorders: a meta-analysis of
 randomised controlled trials. Journal of neurology, neurosurgery, and psychiatry. 2008;79:366-7.

- [7] Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on
 skeletal muscle phosphocreatine resynthesis. The American journal of physiology. 1994;266:E725 30.
- 334 [8] Gualano B, Roschel H, Lancha AH, Jr., Brightbill CE, Rawson ES. In sickness and in health: the 335 widespread application of creatine supplementation. Amino acids. 2012;43:519-29.

- [9] Murphy RM, Stephenson DG, Lamb GD. Effect of creatine on contractile force and sensitivity in
 mechanically skinned single fibers from rat skeletal muscle. American journal of physiology Cell
 physiology. 2004;287:C1589-95.
- 339 [10] Sakkas GK, Schambelan M, Mulligan K. Can the use of creatine supplementation attenuate
 340 muscle loss in cachexia and wasting? Current opinion in clinical nutrition and metabolic care.
 341 2009;12:623-7.
- 342 [11] Wallimann T, Riek U, Moddel M. Intradialytic creatine supplementation: A scientific rationale for
- improving the health and quality of life of dialysis patients. Medical hypotheses. 2017;99:1-14.
- [12] Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program
 for the social, behavioral, and biomedical sciences. Behavior research methods. 2007;39:175-91.
- [13] Green AL, Simpson EJ, Littlewood JJ, Macdonald IA, Greenhaff PL. Carbohydrate ingestion
 augments creatine retention during creatine feeding in humans. Acta physiologica Scandinavica.
 1996;158:195-202.
- 349 [14] Enia G, Sicuso C, Alati G, Zoccali C. Subjective global assessment of nutrition in dialysis patients.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant
 Association European Renal Association. 1993;8:1094-8.
- [15] Steiber AL, Kalantar-Zadeh K, Secker D, McCarthy M, Sehgal A, McCann L. Subjective Global
 Assessment in chronic kidney disease: a review. Journal of renal nutrition : the official journal of the
 Council on Renal Nutrition of the National Kidney Foundation. 2004;14:191-200.
- [16] Neto JF, Ferraz MB, Cendoroglo M, Draibe S, Yu L, Sesso R. Quality of life at the initiation of
 maintenance dialysis treatment--a comparison between the SF-36 and the KDQ questionnaires.
 Quality of life research : an international journal of quality of life aspects of treatment, care and
- 358 rehabilitation. 2000;9:101-7.
- [17] Candow DG, Chilibeck PD, Forbes SC. Creatine supplementation and aging musculoskeletalhealth. Endocrine. 2014;45:354-61.
- [18] Borges MC, Vogt BP, Martin LC, Caramori JC. Malnutrition Inflammation Score cut-off predicting
 mortality in maintenance hemodialysis patients. Clinical nutrition ESPEN. 2017;17:63-7.
- 363 [19] Johnston AP, Burke DG, MacNeil LG, Candow DG. Effect of creatine supplementation during 364 cast-induced immobilization on the preservation of muscle mass, strength, and endurance. Journal
- of strength and conditioning research. 2009;23:116-20.
- 366 [20] Branch JD. Effect of creatine supplementation on body composition and performance: a meta-367 analysis. International journal of sport nutrition and exercise metabolism. 2003;13:198-226.
- 368 [21] Gualano B, Rawson ES, Candow DG, Chilibeck PD. Creatine supplementation in the aging 369 population: effects on skeletal muscle, bone and brain. Amino acids. 2016;48:1793-805.
- [22] Gotshalk LA, Kraemer WJ, Mendonca MA, Vingren JL, Kenny AM, Spiering BA, et al. Creatine
 supplementation improves muscular performance in older women. European journal of applied
 physiology. 2008;102:223-31.
- 373 [23] Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, et al. Mortality risk in
- hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney international.
 2002;62:2238-45.
- [24] Kalantar-Zadeh K, Streja E, Kovesdy CP, Oreopoulos A, Noori N, Jing J, et al. The obesity paradox
 and mortality associated with surrogates of body size and muscle mass in patients receiving
 hemodialysis. Mayo Clinic proceedings. 2010;85:991-1001.
- 379




Figure 1.Study design.

- $(6^{a} wk).$
- LBM: lean body mass; MIS: malnutrition-inflammation score.

^{1&}lt;sup>a</sup> stage: Evaluations (1^awk); 2^a stage: Intervention (2^a to 5^a wk) and 3^a stage: Revaluations




Figure 2.Delta of individual change in lean body mass (%).




Figure 3.Delta of % change in body fat mass (A) and in lean body mass (B) measured bydual X-ray absorptiometry in the treated and control groups.

Table 1.Blindedinterventionprotocol.

Groups	1 st week (loadin	g phase)	2-4 th week		
Groups	four times in day*	total in day	only one time in day#	total in day	
Placebo (maltodextrin)	10g	40g	10g	10g	
Creatine	5g (creatine)	<mark>20g</mark>	5g (creatine)	<mark>5g</mark>	
(maltodextrin + creatine)	+	+	+	+	
(manodexum + creatine)	5g (malto)	20g	<mark>5g (malto)</mark>	<mark>5g</mark> [м6]	

*Breakfast, lunch, snack and dinner; #Lunch or dinner; Maltodextrin with lemon flavor.

¥7. • 11.	Placebo (n=14)	Creatine(n=14)	р	
Variables	Mean ± SEM	Mean ±SEM		
Sex (n) [#]				
Female	5	4	0.68	
Male	9	10		
Age (years)	41.79±2.72	41.86±3.32	0.98	
Body mass index(kg/m ²)	21.93±1.28	22.76 ± 1.41	0.60	
Comorbities (n) [#]				
Hypertension	10	6		
Diabetes	1	1		
Hypertension + Diabetes	0	1	0.15	
Glomerulonephritis	2	0		
Others	1	3		
Unknown	0	3		

Table2. Baseline characteristics.

400 #Chi-square.

Variables	Placebo(n=14)	Creatine(n=14)	n	
v ar lables	Mean±SEM	Mean±SEM	р	
Energy (kcal)	1629.57±265.52	1553.46±157.42	0.80	
Carbohydrate (g)	180.35±26.93	177.91±21.54	0.94	
Total fat (g)	66.90±12.21	64.67±6.64	0.57	
Monounsaturated fat (g)	18.64±2.35	18.30±2.30	0.80	
Polyunsaturated fat (g)	15.81±2.21	15.21±1.81	1.00	
Saturated fat (g)	16.16±2.25	16.17 ± 2.26	0.98	
Cholesterol (mg)	255.75±74.67	272.12±36.83	0.21	
Protein (g)	76.47±14.27	65.96±8.17	0.63	
Protein (g/kg b.w.)	1.31±0.23	1.14±0.16	0.54	
Calcium (mg)	352.75±90.62	367.63±65.16	0.37	
Iron (mg)	8.26±1.15	6.85±0.70	0.35	
Phosphorus (mg)	948.06±184.36	825.70±80.32	1.00	
Magnesium (mg)	177.82±22.17	168.30±20.57	0.70	
Potassium (mg)	1880.31±254.44	1847.39±257.60	0.98	
Sodium (mg)	3860.10±644.30	3551.40±381.10	0.66	
Dietary fiber (g)	16.75±1.96	14.52±1.78	0.35	

Table 3.Food intake among the groups.

402 Mann-Whitney test; b.w.: body weight.

Variables	Placebo (n=14) Mean ± SEM			Creatine (n=14) Mean ± SEM					
	Pre	Post	Δ	Pre	Post	Δ	Δр	Effect size	ANOVA D
MIS	5.71 ± 0.97^{a}	5.36±0.95 ^a	-0.36±0.39	5.57±0.72 ^a	3.85±0.47 ^b #	-1.71±0.37	0.01*	0.964	0.01*
Body composition									
Body weight (kg)	58.91±3.67	59.42±3.69#	0.51±0.21	62.07±4.83	62.84±4.81#	0.77 ± 0.24	0.43	0.301	0.43
Body mass index(kg/m ²)	21.93±1.28	22.13±1.30	0.19±0.09	22.76±1.41	23.04±1.39#	0.27 ± 0.08	0.52	0.245	0.33
Arm circumference (cm)	27.68±1.16	27.81±1.13	0.12±0.23	28.59 ± 1.60	28.38±1.35	-0.20±0.71	0.65	0.160	0.66
Thigh circumference(cm)	45.46±1.86	45.30±1.76	-0.15 ± 0.58	45.61±1.94	45.96±1.93	0.35±0.14	0.41	0.312	0.41
Calf circumference(cm)	33.51±1.17	32.55 ± 0.82	-0.96 ± 0.74	33.77±1.42	$34.04{\pm}1.40$	0.27±0.16	0.11	0.608	0.11
Gait speed (m/s)	0.81±0.03	0.78 ± 0.03	-0.03 ± 0.04	0.72 ± 0.03	0.78±0.03#	0.05 ± 0.02	0.09	0.647	0.22
Lean body mass (kg)	41.33 ± 2.28^{a}	41.46±2.36 ^a	0.13±0.21	$42.96{\pm}2.74^{b}$	43.92±2.71ª#	0.95 ± 0.30	0.03*	0.832	0.03*
Fat body mass (kg)	15.23±2.51 ^a	15.63 ± 2.52^{b} #	0.39±0.12	16.77 ± 2.93^{b}	16.60 ± 2.95 ^b	-0.17±0.01	0.02*	0.903	0.02*
Biochemical parameters									
Creatinine (mg/dL)	5.86±0.60 ^a	5.03±0.45 ^a	-0.82 ± 1.94	4.04 ± 0.49^{b}	5.95±0.84 ^a #	1.90 ± 0.76	0.00*	1.113	0.00*
Urea pre (mg/dL)	136.92 ± 8.05	$150.42{\pm}11.89$	13.50±8.41	133.42±10.76	131.92±8.22	-1.50±7.77	0.20	0.495	0.20
Urea post (mg/dL)	36.79±6.55	30.07±6.76	-6.71±4.21	40.71±7.38	44.86±5.64	4.14±8.16	0.24	0.446	0.24
Phosphorus (mg/dL)	5.32±0.65	5.50±0.89	0.17 ± 0.40	5.71±0.44	5.72±0.46	0.01 ± 0.32	0.76	0.115	0.76


Table 4. Comparison of MIS, body composition and biochemical parameters among the groups.

MIS: malnutrition inflammatory score.

* p<0.05 was considered as significant;#difference vs pre; a≠b difference in two-way ANOVA followed of post hoc Tukey test.

Supplementary Table 1.Quality of life among the groups.

	Placebo (n=14)			Creatine (n=14)					
Domains		Mean ± SEM			Mean ± SEM				
Domanis	Pre	Post	Δ	Pre	Post	Δ	Δ p	Effect size	ANOVA P
Physical function	75.00±6.54	67.50±13.60	-7.50±16.52	71.78±10.19	75.71±10.34	3.92±2.46	0.94	0.258	0.49
Role limitation physical	42.85±9.95	44.64±19.98	1.78±22.76	42.85±13.97	51.78±14.70	8.92±9.66	0.66	0.109	0.77
Pain	55.35±7.39	57.71±10.40	2.35±12.59	62.14±8.90	65.57±8.03	3.42±7.9	0.83	0.027	0.94
General health	49.35±5.15	43.57±8.73	-5.78±11.54	38.71±7.19	40.14±6.14	1.42±4.67	0.91	0.219	0.56
Vitality	53.57±4.23	51.78±8.36	-1.78±9.64	54.28±6.54	60.35±6.51	6.07±3.32	0.73	0.291	0.44
Social function	70.53±5.94	70.53±11.83	0.00±13.55	82.14±7.14	90.17±5.10	8.03±5.17	0.83	0.209	0.58
Emotional function	59.52±12.19	47.61±19.67	-11.90±20.25	47.61±16.65	64.27±15.80	16.66±13.87	0.35	0.439	0.25
Mental health	65.71±6.04	62.28±10.48	-3.42±10.47	69.71±6.47	71.71±4.65	2.00±5.19	0.66	0.175	0.64



Supplementary Figure 1. Participant flowchart (CONSORT).